Anatomical main group
M – MUSKEL- UND SKELETTSYSTEM
12Decisions
27Patient groups
Added benefit by patient group
- Major2
- Considerable1
- Minor2
- Non-quantifiable7
- Not proven15
Subgroups
- M04 GICHTMITTEL 1 decision
- M05 MITTEL ZUR BEHANDLUNG VON KNOCHENERKRANKUNGEN 6 decisions
- M09 ANDERE MITTEL GEGEN STÖRUNGEN DES MUSKEL- UND SKELETTSYSTEMS 5 decisions
Decisions, newest first
- 2026-08-20ColxiColchicinMinor
- 2026-01-22DuvyzatGivinostatNon-quantifiable
- 2024-05-16VoxzogoVosoritidNon-quantifiable
- 2024-03-07EvrysdiRisdiplamNot proven: 3 of 3 patient groups
- 2024-02-15VoxzogoVosoritidNon-quantifiable
- 2023-02-16CrysvitaBurosumabNot proven
- 2022-07-21CrysvitaBurosumabNot proven
- 2022-07-21CrysvitaBurosumabNon-quantifiable
- 2021-11-04ZolgensmaOnasemnogen abeparvovecNot proven: 4 of 4 patient groups
- 2021-10-21EvrysdiRisdiplamNon-quantifiable: 2 of 6 patient groupsNot proven: 4 of 6 patient groups
- 2021-05-20SpinrazaNusinersenMajor: 2 of 6 patient groupsConsiderable: 1 of 6 patient groupsNon-quantifiable: 1 of 6 patient groupsNot proven: 2 of 6 patient groups
- 2020-09-03EvenityRomosozumabMinor
Data status: 2026-10-29